Trials / Completed
CompletedNCT00548834
Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis
Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDP870 |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2004-07-01
- Completion
- 2004-07-01
- First posted
- 2007-10-24
- Last updated
- 2013-09-04
Source: ClinicalTrials.gov record NCT00548834. Inclusion in this directory is not an endorsement.